The European Patent Office Allows Patent for RESP3000

Respiratorius announces that the European Patent Office – EPO has issued a Decision to Grant a patent application for RESP3000 series, designed for use in cardiovascular diagnostics with PET-camera.

Since earlier patents for RESP3000 are issued in the United States, Japan, Israel, Australia, South Africa, and Russia. In addition, a divisional application for RESP3000 on specific product requirements was recently approved in the US during 2017.

The substances in the RESP3000 series specifically binds to mitochondria, and since the heart muscle is rich in mitochondria allowing for high contrast and detailed PET images, which is also confirmed in the completed "proof of concept" study.

Markers for PET-cameras today attracts interest from a diagnostic perspective, since the images results in excellent resolution while the radiation dose can be kept low. This has contributed to a market in strong growth, and thereby a high level of activity in the industry.

"The new patent approval in Europe further strengthens the commercial value of RESP3000 and confirms that we have a strong patent application," says CEO Johan Drott in a comment".

This information is information which Respiratorius AB (publ) is obliged to publish under the EU Market Abuse Regulation. The information was provided by the above contact person's auspices, for publication on February 1, 2018.

Johan Drott
President Respiratorius AB
+46 709-22 41 40
johan.drott@respiratorius.com

Respiratorius AB (publ) is developing drug candidates with the goal to launch drugs for common diseases cancer, chronic obstructive pulmonary disease (COPD) and severe asthma. In addition, the project portfolio is a project for improved diagnosis of certain cardiovascular diseases.

Tags:

Subscribe

Documents & Links

Quotes

The new patent approval in Europe further strengthens the commercial value of RESP3000 and confirms that we have a strong patent application
Johan Drott, CEO and President Respiratorius AB